Page 2 - ichorbio Citations (Resources)

This article is based on research found in the following publication:

Mine, K., Nagafuchi, S., Akazawa, S. et al. TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes. Nat Commun15, 1337 (2024). https://doi.org/10.1038/s41467-024-45573-9

Type 1 diabetes (T1D) is an autoimmune disease where the body's...

A recent study published in Frontiers in Immunology has shed light on a promising new immune checkpoint inhibitor, KVA12123, developed by Kineta Inc. This fully human monoclonal antibody targets VISTA (V-domain Ig suppressor of T cell activation), a key driver of immunosuppression in the tumor microenvironment.

VISTA is primarily expressed on myeloid cells and plays a crucial role in maintaining immune tolerance. However, in cancer, VISTA...

A groundbreaking study by researchers at Princeton University has revealed a promising strategy to enhance the efficacy of cancer immunotherapy by supplementing one-carbon (1C) units, essential building blocks for nucleotide synthesis. The findings, recently published as a preprint on bioRxiv, demonstrate that elevating circulating levels of formate, a key 1C unit donor, can significantly improve the response to ...

In the ever-evolving landscape of cancer immunotherapy, researchers are continually seeking to unravel the intricate mechanisms that govern the body's immune response to tumors. A recent study by Liang et al., published in Cancer Research Communications, sheds light on a...

Triple negative breast cancer (TNBC) remains one of the most challenging breast cancer subtypes to treat, with a poor prognosis despite recent advances in cancer immunotherapy. However, a new study by Travelli et al., published in the Journal for ImmunoTherapy of Cancer, has identified a promising therapeutic target that could potentially revolutionize the treatment of TNBC: extracellular nicotinamide phosphoribosyltransferase (eNAMPT).

eNAMPT...

Radiofrequency ablation (RFA) is a minimally invasive treatment for liver cancer, but its efficacy is often limited by incomplete tumor destruction, especially for larger or irregularly shaped tumors. The residual cancer cells left behind after incomplete RFA (iRFA) tend...

In the ongoing battle against cancer, researchers are constantly seeking novel therapeutic targets to improve patient outcomes. A recent study published in Cancer Research Communications has shed light on the potential of targeting P-selectin glycoprotein ligand-1 (PSGL-1) on tumor-associated macrophages (TAMs) to enhance the efficacy of cancer immunotherapy.

TAMs are a major component of the immune cell population in many human tumors and...

Researchers from Taipei Medical University have made a significant breakthrough in the field of cancer immunotherapy with the development of a series of dual HDAC6/HSP90 inhibitors. These innovative compounds not only directly kill cancer cells but also reprogram the immunosuppressive tumor microenvironment, paving the way for more effective immune-based therapies.

The tumor microenvironment is a complex network of cells and molecules...

In the fast-paced world of cell therapy research, a game-changing study has emerged that could revolutionize the field. Published in Nature Biotechnology, the work by Gravina et al. describes a novel approach to protect therapeutic cells from immune rejection - and it all hinges on a crucial tool provided by...

A groundbreaking study published in the Journal of Hepatology has provided valuable insights into the immune mechanisms and predictors of response and adverse events in hepatocellular carcinoma (HCC) patients treated with anti-PD-1 immune checkpoint blockade (ICB) therapy. The research, led by scientists from Singapore and South Korea, employed cutting-edge single-cell technologies to decipher the complex immune landscape in HCC patients receiving...